For Q3 FY2025 (ended September 30, 2025), Altimmune reported revenue of $5,000, flat year-over-year. Net loss was $22.6 million, a 15.3% increase from the prior year, with diluted EPS of -$0.18. Operating loss widened 11.1% to $24.2 million.
•Revenue remained flat at $5,000.
•Net loss increased 15.3% to $22.6 million.
•Operating loss grew 11.1% to $24.2 million.
•Diluted EPS was -$0.18, improving 30.8% year-over-year.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Altimmune, Inc., a late clinical stage biopharmaceutical company focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. Founded in 1997, the company is headquartered in Gaithersburg, Maryland.
Altimmune, Inc. is a late clinical stage biopharmaceutical company focused on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in Phase 3 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and alcohol-associated liver disease. The company aims to address significant unmet medical needs in liver health through innovative drug development.
On which stock exchange is Altimmune (ALT) listed and in what currency?
Altimmune, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ALT. The company's stock trades in US Dollars (USD), which is the currency of its home country, the United States. Investors can buy and sell ALT shares on this major US exchange during regular trading hours.
What sector and industry does Altimmune operate in?
Altimmune operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on research, development, and potential commercialization of therapies for serious liver diseases. Biotechnology companies like Altimmune use biological processes and living organisms to develop drugs, often targeting complex diseases with high unmet medical needs.
Where is Altimmune headquartered and what markets does it serve?
Altimmune is headquartered in Gaithersburg, Maryland, United States. The company primarily serves the US market, as indicated by its US-based operations and listing on a US exchange. Its focus on liver diseases such as MASH and alcohol-associated liver disease addresses health issues prevalent in the US and globally. While its clinical trials may involve international sites, its core business activities are centered in the United States.
What is Altimmune's lead product candidate and what conditions does it target?
Altimmune's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist. This drug is being developed for multiple indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and alcohol-associated liver disease. Pemvidutide is currently in Phase 3 clinical trials, the final stage before potential regulatory approval. By targeting both GLP-1 and glucagon receptors, it aims to improve metabolic and liver health outcomes.